Bone marrow-derived mesenchymal stem cells for treatment of graft vs. host disease

The aim of two phase II studies is to evaluate the efficacy and safety of expanded allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) in treating patients with refractory chronic or refractory acute graft-versus-host disease (cGvHD or aGvHD respectfully) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).